搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

  1. 首頁(yè)
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human Kallikrein 10,KLK 10 ELISA Kit

Human Kallikrein 10,KLK 10 ELISA Kit

  • 中文名稱(chēng)：
    人激肽釋放酶10(KLK 10)酶聯(lián)免疫試劑盒
  • 貨號(hào)：
    CSB-E10095h
  • 規(guī)格：
    96T/48T
  • 價(jià)格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人激肽釋放酶10(KLK 10)酶聯(lián)免疫試劑盒（CSB-E10095h）為雙抗夾心法ELISA試劑盒，定量檢測(cè)血清、血漿樣本中的KLK10含量。試劑盒檢測(cè)范圍為1.675 ng/mL-40 ng/mL，操作簡(jiǎn)便、特異性強(qiáng)，可廣泛用于細(xì)胞生物學(xué)、分子機(jī)制研究及疾病模型構(gòu)建等科研場(chǎng)景，例如通過(guò)檢測(cè)血清或血漿中KLK 10濃度變化，為腫瘤微環(huán)境、炎癥反應(yīng)或代謝調(diào)控等基礎(chǔ)研究提供數(shù)據(jù)支持，所有應(yīng)用均限于科學(xué)研究目的。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見(jiàn)產(chǎn)品說(shuō)明書(shū)。
  • 別名：
    Breast normal epithelial cell associated serine protease ELISA Kit; Kallikrein related peptidase 10 ELISA Kit; Kallikrein-10 ELISA Kit; Kallikrein10 ELISA Kit; KLK 10 ELISA Kit; KLK10 ELISA Kit; KLK10_HUMAN ELISA Kit; NES 1 ELISA Kit; NES1 ELISA Kit; Normal epithelial cell specific 1 ELISA Kit; Normal epithelial cell-specific 1 ELISA Kit; Protease serine like 1 ELISA Kit; Protease serine-like 1 ELISA Kit; PRSS L1 ELISA Kit; PRSSL 1 ELISA Kit; PRSSL1 ELISA Kit
  • 縮寫(xiě)：
    KLK10
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類(lèi)型：
    serum, plasma
  • 檢測(cè)范圍：
    1.675 ng/mL-40 ng/mL
  • 靈敏度：
    0.7 ng/mL
  • 反應(yīng)時(shí)間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測(cè)波長(zhǎng)：
    450 nm
  • 研究領(lǐng)域：
    Cancer
  • 測(cè)定原理：
    quantitative
  • 測(cè)定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<10%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<15%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human KLK 10 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)
    1:1 Average % 92
    Range % 85-106
    1:2 Average % 91
    Range % 88-97
    1:4 Average % 95
    Range % 90-103
    1:8 Average % 95
    Range % 89-101
  • 回收率：
    The recovery of human KLK 10 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range
    Serum (n=5) 92 89-100
    EDTA plasma (n=4) 95 90-99
  • 標(biāo)準(zhǔn)曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    ng/ml OD1 OD2 Average Corrected
    40 1.956 2.014 1.985 1.931
    20 1.337 1.324 1.331 1.277
    10 0.796 0.808 0.802 0.748
    3.3 0.342 0.355 0.349 0.295
    1.67 0.211 0.215 0.213 0.159
    0 0.053 0.055 0.054 　
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

  • 功能：
    Has a tumor-suppressor role for NES1 in breast and prostate cancer.
  • 基因功能參考文獻(xiàn)：
    1. MiR-199b-5p promotes cell proliferation, migration and suppresses apoptosis in cervical cancer cells. KLK10 is a direct target of miR-199b-5p. MiR-199b-5p expression is increased and positively correlated with KI-67 in human cervical cancer tissues and cell lines. PMID: 29807015
    2. blockade of KLK10 attenuates epithelial-mesenchymal transition and activation of FAK-SRC-ERK signaling, which explains the mechanism of KLK10 in promoting metastasis. PMID: 29621546
    3. To the best of our knowledge, this is the first report on KLK10 exon 3 unmethylated PCR product concentration as potential early epigenetic diagnostic marker in primary ovarian tumors. PMID: 29690914
    4. KLK10 was verified to be a potential therapeutic target for reversing trastuzumab resistance in breast cancer cells. PMID: 27825132
    5. Pronounced correlations between KLK10/KLK11 (rs = 0.647) and between KLK9/KLK15 (rs = 0.716) mRNA, but not between other combinations, indicate coordinate expression of distinct pairs of peptidases PMID: 29095848
    6. identification and molecular cloning of eight novel transcripts of the human KLK10 gene using 3' rapid amplification of cDNA ends (3' RACE) and next-generation sequencing (NGS), as well as their expression analysis in a wide panel of cell lines, originating from several distinct cancerous and normal tissues PMID: 28419837
    7. Data suggest that mature KLK9 (kallikrein 9) is a glycosylated chymotrypsin-like enzyme with strong preference for tyrosine over phenylalanine at P1 cleavage position; substrate specificity of KLK9 appears to extend to KLK10 and midkine; enzyme activity is enhanced by Mg2+ and Ca2+, but is reversibly attenuated by Zn2+; KLK9 is inhibited in vitro by many naturally occurring or synthetic protease inhibitors. PMID: 28559305
    8. KLK10 potentially plays a crucial role in esophageal cancer cell growth. PMID: 26479703
    9. KLK10 may function as a tumour suppressor by repressing proliferation, enhancing apoptosis and decreasing glucose metabolism in PC3 cells. PMID: 26616394
    10. treated and untreated prolactin-producing pituitary adenomas and carcinomas as well as TSH-producing pituitary adenomas and carcinomas were conclusively immunopositive for KLK10 PMID: 25553760
    11. Immunoexpression of KLK10 in the ACTH-secreting tumors as well as in the Crooke cell tumors was significantly increased when compared with the nonfunctioning tumors and in the corticotrophs of non-tumorous pituitaries. PMID: 25517869
    12. is the first correlation of oral squamous cell carcinoma with KLK10 rs3745535G>T polymorphisms PMID: 23413953
    13. KLK10 expression is an independent biomarker of unfavorable prognosis in patients with gastric cancer. PMID: 24409072
    14. Patients with high KLK10 expression had a shorter disease-free and overall survival rates. PMID: 23499583
    15. Enhancing KLK10 gene expression can decrease the proliferation and invasiveness of human tongue cancer cells in vitro. PMID: 23268413
    16. Finding lower KLK10 levels in pleomorphic adenoma suggests aberrant expression in a tumour that develops primarily from myoepithelial cells. A kallikrein cascade may play a role in the development and/or outcome of some salivary gland tumours. PMID: 23250777
    17. KLK10 DNA methylation was significantly associated with prostate cancer. PMID: 22874102
    18. Data indicate a statistically significant positive association between kallikrein-related peptidase 10 (KLK10) and tumor stage and liver metastases. PMID: 22437349
    19. Loss of KLK10 is associated with ovarian cancer. PMID: 22102857
    20. KLK10 gene expression may be used as a marker of unfavorable prognosis for colorectal cancer PMID: 21487810
    21. Single nucleotide polymorphisms in KLK10 is not associated with ovarian cancer. PMID: 20686372
    22. Results indicate that cells underwent EMT exhibited overactive TGFbeta signaling and loss of expression of the CDH1, CGN, CLDN4, and KLK10 genes as a result of hypermethylation of their corresponding promoter regions. PMID: 20086175
    23. NES1/kallikrein 10 mRNA is expressed in normal breast tissue and benign lesions, with loss of NES1/kallikrein 10 expression during tumor progression. PMID: 11705853
    24. Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers. PMID: 11920956
    25. Higher expression in breast cancer predicts tamoxifen resistance PMID: 12087468
    26. kallikrein 10 is expressed in the nonmalignant and malignant prostate, with cancer tissues demonstrating slightly lower expression PMID: 12970725
    27. Downregulation of kallikrein 10 is associated with breast cancer PMID: 14696124
    28. Kallikrein K10 is decreased in cerebrospinal fluid (CSF) of frontotemporal dementia patients and K10 is increased in CSF of Alzheimer patients, compared to control subjects. PMID: 14972646
    29. new splice variants of the KLK10 gene identified; in silico analyses show differential expression of gene in various malignancies and provide basis for directing experimental efforts to investigate possible role of gene as cancer biomarker PMID: 16103744
    30. CpG island hypermethylation plays an important role in the downregulation of kallikrein 10 mRNA and protein expression PMID: 16254462
    31. Kallikrein 10 is highly expressed in uterine serous papillary carcinoma, and it is released in the plasma and serum of uterine serous papillary carcinoma patients. PMID: 16647913
    32. REVIEW of KLK10 gene expression in neoplasm cells PMID: 16800732
    33. functional importance of retinoic acid response elements in the hK10 promoter was demonstrated by retinoid induction of hk10 promoter-reporters PMID: 16800735
    34. results suggest a co-regulation of KLK10 and KLK11 expression in lung and a lack of KLK10 suppressor role in non-small-cell lung cancer PMID: 16800740
    35. KLK10 expression is up-regulated in CRC and GC and higher expression of KLK10 closely correlates with advanced disease stage, which predicts a poorer prognosis. PMID: 16928223
    36. Results suggest that NES1 inactivation might contribute to the malignant progression of human gastric cancers. PMID: 17182177
    37. Glucocorticoid receptor-mediated expression of kallikrein 10 PMID: 17937626
    38. The hormone-specific upregulation of PSA, KLK10 and KLK11 in the breast cancer cell line T47D is dependent on major intracellular signaling pathways. PMID: 18515984
    39. Suppression of gastric cancer growth by baculovirus vector-mediated transfer of normal epithelial cell specific-1 gene. PMID: 18855978
    40. synergistic effects between estrogens and androgens on estrogen-sensitive genes may have implications on the role of the kallikreins 10, 11, and 14 in associated risk of breast cancer and progression. PMID: 19383315
    41. Down-Regulation of KLK10 through DNA Methylation is associated with hepatocellular carcinoma. PMID: 19760608

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Secreted.
  • 蛋白家族：
    Peptidase S1 family, Kallikrein subfamily
  • 組織特異性：
    Expressed in breast, ovary and prostate.
  • 數(shù)據(jù)庫(kù)鏈接：

    HGNC: 6358

    OMIM: 602673

    KEGG: hsa:5655

    STRING: 9606.ENSP00000311746

    UniGene: Hs.275464